Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Wei Yuan
Institution:
Institute of Cancer Research
Observed institution:
Institute of Cancer Research
ORCID:
0000-0001-8004-1846
Observed ORCID:
0000-0001-8004-1846
OpenAlex ID:
A5064039491
RETRACTED ARTICLE: NSD2 targeting reverses plasticity and drug resistance in prostate cancer
2025
·
Jia J. Li
, Alessandro Vasciaveo
, et al.
·
Nature
·
27
NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
2025
·
Jonathan Welti
, Denisa Bogdan
, et al.
·
Clinical Cancer Research
·
12
Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer
2025
·
Juan M. Jiménez-Vacas
, Daniel Westaby
, et al.
·
Nature Communications
·
10
PDF
Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
2026
·
Crescens Tiu
, Wing Yau
, et al.
·
Clinical Cancer Research
·
3
Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer
2024
·
Antje Neeb
, Ines Figueiredo
, et al.
·
Molecular Cancer Therapeutics
·
2
PDF
Commensal Nakaseomyces glabratus migrates into prostate tumors to accelerate cancer progression
2026
·
Ping Lai
, Lei Liu
, et al.
·
Nature Cancer
·
1
PDF
ProMPt: A modular preclinical platform for functional modelling of prostate cancer heterogeneity and therapeutic vulnerabilities
2025
·
Nicole Pandell
, Jacob Househam
, et al.
·
bioRxiv (Cold Spring Harbor Laboratory)
·
1
PDF
Abstract 3415: The neutrophil-to-lymphocyte ratio (NLR) reflects intratumor myeloid derived suppressor cell (MDSC) infiltration in metastatic castration-resistant prostate cancers (mCRPC)
2022
·
Christina Guo
, Jan Rekowski
, et al.
·
Cancer Research
·
1
Supplementary Figure 3 from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
2026
·
Crescens Tiu
, Wing Yau
, et al.
Supplementary Table 4 from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
2026
·
Crescens Tiu
, Wing Yau
, et al.
Data from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
2026
·
Crescens Tiu
, Wing Yau
, et al.
Supplementary Table 3 from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
2026
·
Crescens Tiu
, Wing Yau
, et al.
Supplementary Table 5 from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
2026
·
Crescens Tiu
, Wing Yau
, et al.
Supplemental Tables 1-2 from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
2026
·
Crescens Tiu
, Wing Yau
, et al.
Supplementary Figure 4. from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
2026
·
Crescens Tiu
, Wing Yau
, et al.
Supplementary Figure 5. from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
2026
·
Crescens Tiu
, Wing Yau
, et al.
Supplementary Figure 1-2. from Phase I Trial of Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma
2026
·
Crescens Tiu
, Wing Yau
, et al.
Retraction Note: NSD2 targeting reverses plasticity and drug resistance in prostate cancer
2026
·
Jia J. Li
, Alessandro Vasciaveo
, et al.
·
Nature
PDF
Supplementary Figure 10 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer
2026
·
Antje Neeb
, Ines Figueiredo
, et al.
Supplementary Figure 8 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer
2026
·
Antje Neeb
, Ines Figueiredo
, et al.
Supplementary Table 2 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer
2026
·
Antje Neeb
, Ines Figueiredo
, et al.
Supplementary Figure 5 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer
2026
·
Antje Neeb
, Ines Figueiredo
, et al.
Supplementary Figure 9 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer
2026
·
Antje Neeb
, Ines Figueiredo
, et al.
Supplementary Table 5 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer
2026
·
Antje Neeb
, Ines Figueiredo
, et al.
Supplementary Figure 4 from Thio-2 Inhibits Key Signaling Pathways Required for the Development and Progression of Castration-resistant Prostate Cancer
2026
·
Antje Neeb
, Ines Figueiredo
, et al.
Show more works
View as search
Works count:
84
Citation count:
57
H-index:
3
I10-index:
3
Year
Topic
Type